Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity

https://doi.org/10.1016/j.cell.2021.05.021 2nd June 2021

Article highlights & insights

Cross-presentation of antigens from dead tumor cells by type 1 conventional dendritic cells (cDC1s) is thought to underlie priming of anti-cancer CD8+ T cells. cDC1 express high levels of DNGR-1 (a.k.a. CLEC9A), a receptor that binds to F-actin exposed by dead cell debris and promotes cross-presentation of associated antigens. Here, we show that secreted gelsolin (sGSN), an extracellular protein, decreases DNGR-1 binding to F-actin and cross-presentation of dead cell-associated antigens by cDC1s. Mice deficient in sGsn display increased DNGR-1-dependent resistance to transplantable tumors, especially ones expressing neoantigens associated with the actin cytoskeleton, and exhibit greater responsiveness to cancer immunotherapy. In human cancers, lower levels of intratumoral sGSN transcripts, as well as presence of mutations in proteins associated with the actin cytoskeleton, are associated with signatures of anti-cancer immunity and increased patient survival. Our results reveal a natural barrier to cross-presentation of cancer antigens that dampens anti-tumor CD8+ T cell responses.

Meet the Research Team

Evangelos Giampazolias

Junior Group Leader

Swara Patel
Swara Patel

PhD Student

Alexander Vdovin Postdoctoral Fellow
Alexander Vdovin

Postdoctoral Fellow

non-gendered icon
Pengbo Wang

Scientific Officer

Portrait image of Emma West from Cancer Research UK MI
Emma West

PhD Student

All publications

Filter by group
Filter by group leader
Filter by research topic
Filter by year
Search publications

https://doi.org/10.1186/s12943-024-02157-x

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

12 November 2024

Institute Authors (1)

Amaya Viros

Labs & Facilities

Genome Editing and Mouse Models

array(1) { [0]=> int(2947) }

Research Group

Skin Cancer & Ageing

array(1) { [0]=> int(2344) }

https://doi.org/10.1186/s13045-024-01610-0

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency

8 October 2024

Institute Authors (6)

Georges Lacaud, Mathew Sheridan, Michael Lie-a-ling, Liam Clayfield, Jessica Whittle, Jingru Xu

Research Group

Stem Cell Biology

int(2449)

/wp-content/uploads/2024/11/Annual-Report-2023.pdf

2023 Annual Report

13 September 2024

https://doi.org/10.1126/science.adh7954

Vitamin D regulates microbiome-dependent cancer immunity

25 April 2024

Institute Authors (1)

Evangelos Giampazolias

Research Group

Cancer Immunosurveillance

array(1) { [0]=> int(2341) }

https://doi.org/10.1038/s41684-024-01363-w

Streamlining mouse genome editing by integrating AAV repair template delivery and CRISPR-Cas electroporation

10 April 2024

Institute Authors (1)

Natalia Moncaut

Labs & Facilities

Genome Editing and Mouse Models

array(1) { [0]=> int(2947) }

https://www.biorxiv.org/content/10.1101/2023.12.13.568969v1

A novel human model to deconvolve cell-intrinsic phenotypes of genetically dysregulated pathways in lung squamous cell carcinoma

14 December 2023

Institute Authors (3)

Carlos Lopez-Garcia, Caroline Dive, Anthony Oojageer

Research Group

Translational Lung Cancer Biology

array(1) { [0]=> int(2321) }
Gloved hands filling a stripette white lab coat

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Leukaemia Immunology & Transplantation

The Leukaemia Immunology and Transplantation laboratory aim to develop a comprehensive strategy to prevent post-transplant relapse in patients treated with allogeneic haematopoietic stem cell transplantation – the only curative therapy for many patients with acute myeloid leukaemia (AML) and other poor-risk haematological malignancies.

Patient derived preclinical models reveal novel biology of SCLC

Immune detection of dying tumour cells can elicit cancer immunity when the host permits it

Cancer Research In the Paterson Building
Leukaemia Immunology & Transplantation
Patient derived preclinical models reveal novel biology of SCLC

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Institute life in Manchester

We strive to make our community a welcoming, caring and enthusiastic one, fuelling ambition with opportunities for training and mentoring to help us all achieve our personal and professional goals.

“We are so pleased to have received the funding to enable us to test our hypothesis in the lab. If we can create a new medicine that can precisely target a specific type of cell within the tumour, and restore anti-cancer immune responses, this will be a game-changer for oesophageal cancer patients “

Sara Valpione

Former Institute Clinical Fellow and now Clinician in Residence within the CRUK National Biomarker Centre

“My charity bake sales – known as “David’s Great British Bake Off” – are always a hit, home baked products taste so much better than shop bought and are greatly appreciated by staff!”

David Jenkins

Purchasing Officer

“We’ve seen some remarkable responses, with an improvement for some patients within days. This is an early phase trial so there’s a lot more work to do. But the data we have so far is very encouraging and could help many thousands of people in the future”

Tim Somervaille

Senior Group Leader

“It is a pleasure to introduce my team who work to deliver our research goals. We work in a friendly and collaborative environment, supporting each other’s projects.  “

Amaya Virós

CRUK Advanced Clinician Scientist Fellow